Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom

Natera Analyst Ratings

Benzinga09:00 ET · Ratings

Gilead Sciences Says Committee For Medicinal Products For Human Use Of European Medicines Agency Recommends Seladelpar For Treatment Of Primary Biliary Cholangitis In Combination With Ursodeoxycholic Acid (UDCA) In Adults With Inadequate Response To...

Benzinga06:42 ET

Thursday Ends in Index Declines | Wall Street Today

Kevin Travers16:29 ET

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing

Benzinga13:13 ET

Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock

Kevin Travers11:21 ET

Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites

BenzingaDec 12 08:06 ET

$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today

BenzingaDec 11 16:00 ET

Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock

Kevin TraversDec 11 10:47 ET

BofA Restarts Coverage of 11 Large-cap Biopharmas

Seeking AlphaDec 10 17:01 ET

Market Falls Wednesday, but Googles Chip Impresses | WST

Kevin TraversDec 10 16:19 ET

10 Health Care Stocks With Whale Alerts In Today's Session

BenzingaDec 10 12:35 ET

Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock

Kevin TraversDec 10 10:51 ET

Incyte's Late-Breaking ASH 2024 Data Show Tafasitamab (Monjuvi) Significantly Improves Progression-Free Survival In Relapsed/Refractory Follicular Lymphoma, Meeting Phase 3 InMIND Trial Endpoints; U.S. SBLA Filing Planned By Year-End 2024

BenzingaDec 10 10:30 ET

B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target

BenzingaDec 10 07:24 ET · Ratings

Gilead Sciences Analyst Ratings

BenzingaDec 10 05:41 ET · Ratings

Gilead Company Kite Reports Results From Five-year Follow-up Analysis Of ZUMA-5, A Phase 2 Study Of Yescarta

BenzingaDec 9 17:58 ET

Kite, A Gilead Company Presents Longest Follow-Up Data Reported For Tecartus CAR T-Cell Therapy At ASH 2024 Reinforce Durable Efficacy And Survival Benefits; ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, In...

BenzingaDec 9 16:34 ET

Vertex Upgraded to Buy by Jefferies on Fundamentals, Pipeline

Seeking AlphaDec 9 15:47 ET

Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock

BenzingaDec 9 13:23 ET

Vertex Reports Positive Long-term Data for Casgevy

Seeking AlphaDec 9 12:17 ET